{"entity":{"id":"advenchen-laboratories","kind":"company","name":"Advenchen Laboratories","aka":["Advenchen Laboratories, LLC","Advenchen"],"tldr":"Advenchen is the small Californian company that discovered anlotinib, the multi-kinase inhibitor that became one of China's most used cancer pills, and it leads late-stage trials of related compounds.","summary":"Advenchen Laboratories, based in Moorpark, California, designs kinase inhibitors and licenses them to partners. Its anlotinib (AL3818), licensed to Chia Tai Tianqing, is approved in China for lung cancer, soft tissue sarcoma, medullary thyroid cancer and small cell lung cancer, and Advenchen itself sponsors phase 3 trials of anlotinib and catequentinib outside China. Its records appear on ClinicalTrials.gov under the Advenchen name.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://advenchen.com"},{"label":"ClinicalTrials.gov: trials led by Advenchen Laboratories, LLC","url":"https://clinicaltrials.gov/search?lead=Advenchen%20Laboratories%2C%20LLC"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q140046417"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["anlotinib","al8326"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct03016819","nct05363280","nct07392736"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Moorpark, CA","country":"US","companyType":"biotech","website":"https://advenchen.com","stage":"private-large","investors":[],"funding":[]},"route":"/companies/advenchen-laboratories/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"drug":[{"id":"al8326","kind":"drug","name":"AL8326","route":"/drugs/al8326/"},{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}],"trial":[{"id":"nct07392736","kind":"trial","name":"A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.","route":"/trials/nct07392736/"},{"id":"nct06247605","kind":"trial","name":"A Phase IIII Study of AL8326 in Small Cell Lung Cancer","route":"/trials/nct06247605/"},{"id":"nct05363280","kind":"trial","name":"Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment","route":"/trials/nct05363280/"},{"id":"nct03016819","kind":"trial","name":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)","route":"/trials/nct03016819/"}]}}